The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1566
ISSUE 1566
February 25, 2019
Issue 1566
- An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
- Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
- Fostamatinib (Tavalisse) for ITP
- Oxybutynin for Hot Flashes in Women with Breast Cancer
- Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
- Elderberry for Influenza
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
February 25, 2019 (Issue: 1566)
The FDA has approved a manually
injected, single-dose, prefilled
epinephrine syringe (Symjepi –
Adamis/Sandoz) for emergency
treatment of anaphylaxis. The new
device is approved in 0.3- and
0.15-mg strengths for treatment of
patients...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.